Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980874 | 0.85 | KMT2A (0.52) | KMT2AL3MBTL1KDM1AMAOBCA12 | |
| SCHEMBL30848506 | 0.77 | KMT2A (0.46) | KMT2AL3MBTL1KDM1AMAOBKCNA3 | |
| SCHEMBL1503975 | 0.77 | CPB1 (0.44) | KMT2AL3MBTL1KDM1AMAOBCA1 | |
| SCHEMBL742035 | 0.74 | KDM4E (0.34) | KMT2AGRIN2BNFKB1 | |
| SCHEMBL1503774 | 0.74 | BTK (0.40) | KMT2AKDM1AMAOBRORCNFKB1 | |
| SCHEMBL2180797 | 0.73 | UBE2M (0.55) | KMT2AL3MBTL1MAOBKCNA3DRD2 | |
| SCHEMBL2180789 | 0.73 | UBE2M (0.55) | KMT2AL3MBTL1MAOBKCNA3DRD2 | |
| SCHEMBL2180793 | 0.73 | UBE2M (0.55) | KMT2AL3MBTL1MAOBKCNA3DRD2 | |
| SCHEMBL1504585 | 0.73 | BTK (0.37) | KMT2AL3MBTL1KDM1AMAOBRORC | |
| SCHEMBL740804 | 0.73 | BTK (0.37) | KMT2AL3MBTL1KDM1AMAOBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | KMT2A 3485/4885L3MBTL1 385/4885KDM1A 3565/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | KMT2A 3179/4885L3MBTL1 309/4885KDM1A 3445/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | KMT2A 3485/4885L3MBTL1 385/4885KDM1A 3565/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | KMT2A 1453/4885L3MBTL1 4055/4885KDM1A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.